|
Mar 14
|
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 1
|
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
|
|
Feb 27
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
|
|
Dec 18
|
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 14
|
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
|
|
Nov 8
|
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
|
|
Nov 3
|
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
|